by NImmune Biopharma | Nov 2, 2023 | Press Release
This publication describes novel LANCL2-based immunoregulatory mechanisms that enhance regulatory T cells (Tregs) anti-inflammatory functions by amplifying IL-2 signaling and promote T cell metabolic reprogramming resulting in enhanced mitochondrial metabolism...
by NImmune Biopharma | Nov 2, 2023 | Research and White Papers
Lanthionine synthetase C-like 2 (LANCL2) therapeutics have gained increasing recognition as a novel treatment modality for a wide range of autoimmune diseases. Genetic ablation of LANCL2 in mice results in severe inflammatory phenotypes in inflammatory bowel disease...
by NImmune Biopharma | Oct 23, 2023 | Press Release
Download Press Release Once-a-day oral dosing with omilancor induced clinical remission in 30.4% of active Ulcerative Colitis (UC) patients versus 3.7% in the placebo group (Δ=26.7%, P = 0.01) Once-a-day oral dosing with omilancor in active Crohn’s disease (CD)...
by NImmune Biopharma | Aug 10, 2023 | Research and White Papers
Clostridioides difficile infection (CDI) is an opportunistic infection of the gastrointestinal tract, commonly associated with antibiotic administration, that afflicts almost 500 000 people yearly only in the United States. CDI incidence and recurrence is increased...
by NImmune Biopharma | Jun 23, 2023 | News
Many of the available treatments for the autoimmune conditions ulcerative colitis (UC) and Crohn’s disease come with drawbacks such as safety issues or inconvenient dosing regimens. Describing itself as a biomarker-driven immunoregulatory therapeutics company, Nimmune...
